Novartis India launches Pluvicto, an advanced prostate cancer treatment, in the country, according to reports from The Hindu and Business Line. Pluvicto is described as a radioligand therapy, aimed at treating patients with prostate cancer. Business Line quotes Novartis India saying Pluvicto is the first radioligand therapy in India that has received approval from the relevant regulatory authority for patients. The reports present the launch as an expansion of available therapeutic options for prostate cancer in India, highlighting both the drug’s advanced nature and its approved status. No additional clinical details, such as specific patient eligibility, dosing, pricing, or availability timelines, are included in the excerpts provided. Overall, the sources agree on the launch of Pluvicto in India and the claim that it is the first regulatory authority-approved radioligand therapy of its kind for patients.